Predictive Oncology’s (POAI) “Sell (E+)” Rating Reaffirmed at Weiss Ratings

Predictive Oncology (NASDAQ:POAI)‘s stock had its “sell (e+)” rating restated by investment analysts at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

Predictive Oncology Trading Down 5.5%

POAI stock opened at $8.01 on Friday. The business’s 50-day moving average price is $13.58 and its two-hundred day moving average price is $13.68. The firm has a market cap of $6.09 million, a PE ratio of -0.39 and a beta of 1.32. Predictive Oncology has a 1-year low of $8.01 and a 1-year high of $45.90.

Predictive Oncology (NASDAQ:POAI) last issued its quarterly earnings results on Wednesday, August 13th. The medical instruments supplier reported ($3.30) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($1.95). The firm had revenue of $0.00 million during the quarter, compared to the consensus estimate of $1.50 million. Predictive Oncology had a negative net margin of 587.31% and a negative return on equity of 722.01%. On average, analysts forecast that Predictive Oncology will post -2.08 earnings per share for the current year.

About Predictive Oncology

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.